Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of AK115 in Healthy Subjects
NCT05286970Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of luvagrobart in pain and cancer pain (6 arms), sponsored by Akeso, Inc. Primary endpoint: Incidence and severity classification of adverse events. Started Mar 2022; status: completed.
02
Drugs
luvagrobart
03
Conditions
paincancer pain
Beyond the preview
Go deeper on NCT05286970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286970.